コンテンツへスキップ
Merck
すべての画像(1)

主要文書

すべての文書を表示

安全性情報

C-053

Supelco

Carbamazepine solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

ログイン組織・契約価格を表示する
すべての画像(1)

About This Item

実験式（ヒル表記法）:
C15H12N2O
CAS番号:
298-46-4
分子量:
236.27
MDL番号:
MFCD00005073
UNSPSCコード:
41116107
NACRES:
NA.24

グレード

certified reference material

品質水準

300

形状

liquid

特徴

SNAP-N-SPIKE®, SNAP-N-SHOOT®

包装

ampule of 1 mL

メーカー／製品名

Cerilliant®

濃度

1.0 mg/mL in methanol

テクニック

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

アプリケーション

clinical testing

フォーマット

single component solution

保管温度

−20°C

SMILES記法

O=C(N)N1C2=C(C=CC=C2)C=CC3=C1C=CC=C3

InChI

1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)

InChI Key

FFGPTBGBLSHEPO-UHFFFAOYSA-N

遺伝子情報

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

詳細

Carbamazepine is an anticonvulsant and mood stabilizing drug used primarily in the treatment of epilepsy and neuropathic pain. Marketed under trade names including Carbatrol®, Tegretol®, Carbamaze, and Biston, carbamazepine is also used as a second line treatment for bipolar disorder and in conjunction with antipsychotic drugs for schizophrenia. Suitable uses of this Certified Spiking Solution® include as starting material for preparation of calibrators and controls in carbamazepine testing methods by GC/MS or LC/MS for clinical toxicology, pain prescription monitoring, forensic analysis, or therapeutic drug monitoring applications.

アプリケーション


  • Carbamazepine research solution: A study focuses on the development of cobalt-nitrogen co-doped carbon nanotubes for the activated peroxymonosulfate degradation of Carbamazepine, highlighting its applications in environmental cleanup and pollution control (Molecules, 2024; doi: 10.3390/molecules29071525).

  • Anticonvulsant biochemical reagent: Carbamazepine is utilized in research involving the production and characterization of activated carbon for removing pharmaceutical pollutants from various water sources, demonstrating its relevance in sustainable water treatment technologies. (Materials, Basel).

  • Neuroscience research chemicals: Investigations into novel composite materials for the removal of pharmaceuticals from water matrices include Carbamazepine as a target contaminant, emphasizing its importance in studies related to environmental health and safety (Environ Res, et.al).

  • Ion channel inhibitor: Research into new materials for drug residue removal includes Carbamazepine, showcasing its utility in evaluating the performance of innovative water treatment solutions (Carbohydr Polym, 2024).

  • Epilepsy pharmacological studies: A study involving the LED-driven photo-Fenton process for micropollutant removal highlights the application of Carbamazepine in assessing the efficacy of advanced oxidative processes for environmental decontamination (J Environ Manage, 2024).

法的情報

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Carbatrol is a registered trademark of Pharmavene, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Tegretol is a registered trademark of Novartis Corporation

ピクトグラム

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

シグナルワード

Danger

危険有害性の分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - Skin Sens. 1 - STOT SE 1

ターゲットの組織

Eyes

保管分類コード

3 - Flammable liquids

WGK

WGK 1

引火点(°F)

49.5 °F - closed cup

引火点(℃)

9.7 °C - closed cup

適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

消防法

第4類:引火性液体
アルコール類
危険等級II

Jan Code

C-053-1ML:4548173346069
C-053-CC:

試験成績書（COA）

製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

この製品を見ている人はこちらもチェック

Slide 1 of 10

1 of 10

カルバマゼピン powder

Sigma-Aldrich

C4024

カルバマゼピン

カルバマゼピン United States Pharmacopeia (USP) Reference Standard

USP

1093001

カルバマゼピン

カルバマゼピン meets USP testing specifications

Sigma-Aldrich

C8981

カルバマゼピン

Lidocaine solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

L-018

Lidocaine solution

カルバマゼピン 10,11-エポキシド analytical standard

Supelco

C4206

カルバマゼピン 10,11-エポキシド

クロルプロマジン 塩酸塩 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Supelco

C-904

クロルプロマジン 塩酸塩

レベチラセタム 溶液 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

L-020

レベチラセタム 溶液

10,11-Dihydro-10-hydroxycarbamazepine analytical standard

Supelco

61347

10,11-Dihydro-10-hydroxycarbamazepine

cis-トラマドール 塩酸塩 溶液 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Supelco

T-027

cis-トラマドール 塩酸塩 溶液

フェノバルビタール 溶液 1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

P-008

フェノバルビタール 溶液

Inge Anita Meijer et al.
Muscle & nerve, 49(1), 134-138 (2013-07-31)
Erythromelalgia due to heterozygous gain-of-function SCN9A mutations usually presents as a pure sensory-autonomic disorder characterized by recurrent episodes of burning pain and redness of the extremities. We describe a patient with an unusual phenotypic presentation of gross motor delay, childhood-onset
Emilie Caietta et al.
Pediatrics, 132(3), e784-e787 (2013-08-21)
Mutations of SCN4A encoding the skeletal muscle sodium channel Nav 1.4 cause several types of disease, including sodium channel myotonias. The latter may be responsible for neonatal symptoms, including severe neonatal episodic laryngospasm (SNEL). Establishing the diagnosis of SCN4A-related SNEL
V L Yip et al.
Clinical pharmacology and therapeutics, 92(6), 757-765 (2012-11-08)
Carbamazepine (CBZ) therapy is associated with cutaneous adverse reactions in up to 10% of patients. Predisposition to these hypersensitivity reactions has been linked to the human leukocyte antigen (HLA) genotype. This systematic review determines the strength of these associations and
Janneke Jentink et al.
BMJ (Clinical research ed.), 341, c6581-c6581 (2010-12-04)
To identify specific major congenital malformations associated with use of carbamazepine in the first trimester of pregnancy. A review of all published cohort studies to identify key indications and a population based case-control study to test these indications. Review of
U Amstutz et al.
Clinical pharmacology and therapeutics, 94(1), 142-149 (2013-04-17)
The occurrence of hypersensitivity reactions including rare but life-threatening Stevens-Johnson syndrome (SJS) and drug-induced hypersensitivity syndrome (HSS) limits the use of the anticonvulsant carbamazepine (CBZ). Human leukocyte antigen-B (HLA)-B 15:02 and HLA-A 31:01 have been identified as predictive genetic markers
関連する文献をすべて表示

資料

Protein Binding Determination Using Supel™ BioSPME C18 Pin Device as Part of the Manual Methodology With and Without Shaking

The application note describes a comparative analysis of plasma protein binding results for free/bound drugs using two different sample extraction steps, with and without agitation.

Speed, Simplicity and Accuracy of Protein Binding Determination using BioSPME

Learn about Supel™ BioSPME C18 high-throughput devices to determine plasma protein binding and decrease the sample preparation time to less than an hour.

Protein Binding Determination - Comparison Study of Techniques & Devices

Comparative analysis of Supel™ BioSPME 96-Pin device with a rapid equilibrium dialysis technique for accuracy of measured values, sample cleanliness, and workflow time in drug protein binding.

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら（テクニカルサービス）